Philip C. Schouten

Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial

Leonie Voorwerk, Maarten Slagter, Hugo M. Horlings et al. · Nature Medicine · 2019 · 889 citations · Full text

Medicine, Immunology, Oncology +17

REV7 counteracts DNA double-strand break resection and affects PARP inhibition

Guotai Xu, J. Ross Chapman, Inger Brandsma et al. · Nature · 2015 · 592 citations · Full text

Life Sciences, Cancer Biology, Molecular Biology +14

Frequent Homologous Recombination Deficiency in High-grade Endometrial Carcinomas

Marthe M. de Jonge, Aurélie Auguste, Lise M. van Wijk et al. · Clinical Cancer Research · 2018 · 209 citations · Full text

Life Sciences, Genetics, Molecular Genetics +16

Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer

Magali Michaut, Suet‐Feung Chin, Ian J. Majewski et al. · Scientific Reports · 2016 · 179 citations · Full text

Medicine, Molecular Biology, Oncology +17

The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting

Tesa Severson, Denise M. Wolf, Christina Yau et al. · Breast Cancer Research · 2017 · 74 citations · Full text

Medicine, Biostatistics, Oncology +17